User login
Key clinical point: Delgocitinib ointment was effective and safe for up to 56 weeks in pediatric patients with atopic dermatitis (AD).
Major finding: By the end of initial 4-week treatment, least-squares mean percentage change from baseline in the modified Eczema Area and Severity Index (mEASI) score was significantly greater for delgocitinib vs vehicle (−39.3% vs +10.9%; P less than .001) groups. Improvement in mEASI score continued through the 52-week extension phase. Treatment-related mild adverse events were reported by only 9.7% of patients.
Study details: Findings are from a phase 3 study including 137 Japanese patients aged 2-15 years with mild/moderate/severe AD randomly allocated to either delgocitinib (0.25%) or vehicle ointment for 4 weeks. Eligible patients entered the 52-week extension study phase to receive 0.25% or 0.5% delgocitinib ointment.
Disclosures: This study was funded by Japan Tobacco Inc. and Torii Pharmaceutical Co, Ltd. Some of the authors declared receiving consulting fees, research grants, speaker honoraria, and/or advisory board honoraria from various sources including Japan Tobacco Inc. Two authors declared being employees of Japan Tobacco Inc.
Source: Nakagawa H et al. J Am Acad Dermatol. 2021 Jun 9. doi: 10.1016/j.jaad.2021.06.014.
Key clinical point: Delgocitinib ointment was effective and safe for up to 56 weeks in pediatric patients with atopic dermatitis (AD).
Major finding: By the end of initial 4-week treatment, least-squares mean percentage change from baseline in the modified Eczema Area and Severity Index (mEASI) score was significantly greater for delgocitinib vs vehicle (−39.3% vs +10.9%; P less than .001) groups. Improvement in mEASI score continued through the 52-week extension phase. Treatment-related mild adverse events were reported by only 9.7% of patients.
Study details: Findings are from a phase 3 study including 137 Japanese patients aged 2-15 years with mild/moderate/severe AD randomly allocated to either delgocitinib (0.25%) or vehicle ointment for 4 weeks. Eligible patients entered the 52-week extension study phase to receive 0.25% or 0.5% delgocitinib ointment.
Disclosures: This study was funded by Japan Tobacco Inc. and Torii Pharmaceutical Co, Ltd. Some of the authors declared receiving consulting fees, research grants, speaker honoraria, and/or advisory board honoraria from various sources including Japan Tobacco Inc. Two authors declared being employees of Japan Tobacco Inc.
Source: Nakagawa H et al. J Am Acad Dermatol. 2021 Jun 9. doi: 10.1016/j.jaad.2021.06.014.
Key clinical point: Delgocitinib ointment was effective and safe for up to 56 weeks in pediatric patients with atopic dermatitis (AD).
Major finding: By the end of initial 4-week treatment, least-squares mean percentage change from baseline in the modified Eczema Area and Severity Index (mEASI) score was significantly greater for delgocitinib vs vehicle (−39.3% vs +10.9%; P less than .001) groups. Improvement in mEASI score continued through the 52-week extension phase. Treatment-related mild adverse events were reported by only 9.7% of patients.
Study details: Findings are from a phase 3 study including 137 Japanese patients aged 2-15 years with mild/moderate/severe AD randomly allocated to either delgocitinib (0.25%) or vehicle ointment for 4 weeks. Eligible patients entered the 52-week extension study phase to receive 0.25% or 0.5% delgocitinib ointment.
Disclosures: This study was funded by Japan Tobacco Inc. and Torii Pharmaceutical Co, Ltd. Some of the authors declared receiving consulting fees, research grants, speaker honoraria, and/or advisory board honoraria from various sources including Japan Tobacco Inc. Two authors declared being employees of Japan Tobacco Inc.
Source: Nakagawa H et al. J Am Acad Dermatol. 2021 Jun 9. doi: 10.1016/j.jaad.2021.06.014.